Lv63
1770 积分 2025-04-15 加入
Biomimetic nanoplatform with microbiome modulation and antioxidant functions ameliorating insulin resistance and pancreatic β-cell dysfunction for T2DM management
1个月前
已完结
Sex-specific and BMI-specific associations between visceral fat and diabetic kidney disease in patients with diabetes: a large-scale multicentre prospective cohort study
1个月前
已完结
Reconstruction of endocrine subtype-complete human pluripotent stem cell-derived islets with capacity for hypoglycemia protection in vivo
1个月前
已完结
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
5个月前
已完结
Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial
6个月前
已完结
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
6个月前
已完结
Mapping the effectiveness and risks of GLP-1 receptor agonists
8个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
8个月前
已关闭
Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
9个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
9个月前
已完结
皖公网安备34019202002308
